Our approach harnesses the novel GASP-1 biomarker, which is detectable in serum at very low levels and correlates strongly with early disease progression. Unlike traditional biomarkers that require invasive biopsies or only appear in late-stage disease, our biomarker offers a truly non-invasive, early detection platform with the potential to transform patient outcomes.

GASP-1 (G-protein coupled receptor-associated sorting protein 1) is a protein involved in cellular trafficking pathways and has shown consistent overexpression in the earliest stages of cancer and Alzheimer’s. By quantifying GASP-1 in serum, we can detect disease-associated changes before clinical symptoms or imaging evidence appear.

We are developing both laboratory-grade ELISA kits and rapid point-of-care tests. The ELISA kits enable high-throughput testing in research and clinical laboratories, while our point-of-care tests offer quick, actionable results in clinics and physician offices—opening new pathways for routine early screening.

Current biomarker tests often detect diseases too late or rely on imaging and biopsies. Our serum-based biomarkers fill a critical gap by enabling blood-based early detection with high accuracy and specificity. This positions us uniquely in the market for early-stage detection across multiple cancer types and Alzheimer’s disease.

We actively seek partnerships with biotechnology companies, diagnostics developers, and healthcare providers interested in integrating our biomarkers into their platforms or co-developing applications. We also welcome scientific collaborations to explore new indications for our biomarker approach.